According to Boji Pharmaceutical's announcement, controlling shareholder Wang Tingchun and co-actors Zhao Lingli and Fermi reduced their holdings of the company's shares by 8.425,800 shares in 2025, accounting for 2.18% of the total share capital. From June 30, 2021 to December 3, 2025, the total shareholding ratio of the three was reduced from 38.55% to 35%, and changes in equity reached whole multiples of 1% and 5%. This change in equity will not lead to a change in the company's control, and the holdings reduction plan has not yet been implemented.

According to Boji Pharmaceutical's announcement, controlling shareholder Wang Tingchun and co-actors Zhao Lingli and Fermi reduced their holdings of the company's shares by 8.425,800 shares in 2025, accounting for 2.18% of the total share capital. From June 30, 2021 to December 3, 2025, the total shareholding ratio of the three was reduced from 38.55% to 35%, and changes in equity reached whole multiples of 1% and 5%. This change in equity will not lead to a change in the company's control, and the holdings reduction plan has not yet been implemented.